Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07010159 · ClinicalTrials.gov registry record · Phase 2

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis

A Phase 2 study of Recurrent Pericarditis and Pericarditis, sponsored by Kiniksa Pharmaceuticals International.

Recruiting
Registry status
Phase 2
Development phase
165
Enrollment target
20
Study locations

NCT07010159 is a Phase 2 study of Recurrent Pericarditis and Pericarditis that is actively recruiting participants, run by Kiniksa Pharmaceuticals International. The registered enrollment target is 165 participants, below the 185-participant average among 4 other Recurrent Pericarditis trials with a reported enrollment target (11% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07010159, a Phase 2 study of Recurrent Pericarditis and Pericarditis, is actively recruiting participants, sponsored by Kiniksa Pharmaceuticals International.

RECRUITING
Registry status
Phase 2
Development phase
165 participants
Enrollment target
20
Study locations

Study Summary

This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.

Conditions Studied

Recurrent Pericarditis Pericarditis Pericarditis Acute

Interventions

  • DRUG Placebo
  • DRUG KPL-387

Study Locations (20)

California

  • Investigational Site 030 - Los Angeles
  • Investigational Site 008 - San Francisco

New York

  • Investigational Site 015 - New York
  • Investigational Site 022 - New York

Ohio

  • Investigational Site 009 - Cincinnati
  • Investigational Site 003 - Cleveland

Texas

  • Investigational Site 005 - Austin
  • Investigational Site 013 - Houston

Virginia

  • Investigational Site 006 - Charlottesville
  • Investigational Site 023 - Norfolk

Other

  • Investigational Site 028 - Montpellier
  • Investigational Site 021 - Paris

Arizona

  • Investigational Site 018 - Gilbert

Colorado

  • Investigational Site 016 - Westminster

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2025-07-25
Est. Completion 2029-12-31
Phase Phase 2

Sponsor

Kiniksa Pharmaceuticals International

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07010159

The ClinicalTrials.gov registry entry for NCT07010159 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 185-participant average among 4 other Recurrent Pericarditis trials with a reported enrollment target (11% lower). The listed sponsor is Kiniksa Pharmaceuticals International, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Recurrent Pericarditis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07010159 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT07010159 about?

NCT07010159 is a clinical study titled "Phase 2/3 Study of KPL-387 in Recurrent Pericarditis". This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.

What is the current status of trial NCT07010159?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2025-07-25. Estimated completion is 2029-12-31.

What conditions does trial NCT07010159 study?

This clinical trial studies the following conditions: Recurrent Pericarditis, Pericarditis, Pericarditis Acute.

What interventions are being tested in trial NCT07010159?

The interventions under investigation include: Placebo (DRUG), KPL-387 (DRUG).

Who is sponsoring clinical trial NCT07010159?

This trial is sponsored by Kiniksa Pharmaceuticals International, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07010159 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Pericarditis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Pericarditis

All registered trials for this condition

Pericarditis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.